nCentral Oregon Radiology Associates, Bend, Oregon. oSpecialty Chair, NYU Clinical Cancer Center, New York, New York. The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document. Reprint requests to: publications@acr.org FDG-PET Breast Dedicated There is no relevant literature to support the use of fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET breast for screening in this clinical setting. Mammography Screening Annual screening with 2-D mammography or DBT is recommended for the contralateral native breast. There is insufficient evidence to support screening with 2-D mammography of the postmastectomy side. Although one small retrospective study has shown a small increase in cancer detection with mammography in postmastectomy patients [16], another study has demonstrated no benefit [8]. MRI Breast Without IV Contrast There is no relevant literature to support the use of MRI breast without intravenous (IV) contrast for screening in this clinical setting. MRI Breast Without and With IV Contrast There is no relevant literature to support the use of MRI without and with IV contrast, specifically for screening the postmastectomy nonreconstructed breast. However, based on breast cancer risk, including factors such as age at cancer diagnosis, breast density, and family history, women with a personal history of cancer may undergo MRI for the contralateral native breast [17]. In this setting, the postmastectomy breast may be imaged and evaluated on MRI with potential for malignancy detection and characterization [18]. Sestamibi MBI There is no relevant literature to support the use of Tc-99m sestamibi molecular breast imaging (MBI) for screening in this clinical setting.
Imaging after Mastectomy and Breast Reconstruction. nCentral Oregon Radiology Associates, Bend, Oregon. oSpecialty Chair, NYU Clinical Cancer Center, New York, New York. The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document. Reprint requests to: publications@acr.org FDG-PET Breast Dedicated There is no relevant literature to support the use of fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET breast for screening in this clinical setting. Mammography Screening Annual screening with 2-D mammography or DBT is recommended for the contralateral native breast. There is insufficient evidence to support screening with 2-D mammography of the postmastectomy side. Although one small retrospective study has shown a small increase in cancer detection with mammography in postmastectomy patients [16], another study has demonstrated no benefit [8]. MRI Breast Without IV Contrast There is no relevant literature to support the use of MRI breast without intravenous (IV) contrast for screening in this clinical setting. MRI Breast Without and With IV Contrast There is no relevant literature to support the use of MRI without and with IV contrast, specifically for screening the postmastectomy nonreconstructed breast. However, based on breast cancer risk, including factors such as age at cancer diagnosis, breast density, and family history, women with a personal history of cancer may undergo MRI for the contralateral native breast [17]. In this setting, the postmastectomy breast may be imaged and evaluated on MRI with potential for malignancy detection and characterization [18]. Sestamibi MBI There is no relevant literature to support the use of Tc-99m sestamibi molecular breast imaging (MBI) for screening in this clinical setting.